Cite
Hamran, S.; Al-Rajhi, A.A.; Jasim, K.; Al-Theyab, M.A.; Elahtam, M.; Al-Hail, M.K.; Al-fahaidi, W.; Khamis, Y.; Elzouki, A.; Chivese, T. Efficacy and safety of adding ribavirin to direct-acting antivirals (DAAs) in re-treating non-genotype1 hepatitis C- a systematic review and meta-analysis., in Proceedings of the 1st International Online Conference on Diseases, 9–11 September 2025, MDPI: Basel, Switzerland, doi: